Home > Haematology > EHA 2020 > Myeloid > OS benefit in VIALE-C trial

OS benefit in VIALE-C trial

Presented By
Prof. Andrew Wei, Monash University, Australia
EHA 2020
Phase 3, VIALE-C
The extended findings from the phase 3 VIALE-C trial position low-dose cytarabine (LDAC) plus the BCL-2 inhibitor venetoclax "as a potential new standard of care" for untreated acute myeloid leukaemia (AML) patients ineligible for intensive chemotherapy. Prof. Andrew Wei (Monash University, Australia) presented the updated 18-month findings from the phase 3 VIALE-C AML trial [1]. The 12 month follow-up data were recently published in the journal Blood [2]. In VIALE-C, 211 AML patients were randomised to daily oral venetoclax 600 mg (n=143) or to placebo (n=68) in 28-day cycles, on top of a backbone therapy of LDAC 20 mg/m2 administered subcutaneously on days 1-10 of each cycle. The primary endpoint was...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on